Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis

Cancer

Volumn 112, Issue 7, 2008, Pages 1462-1470

  Kwon, In Kiu ^a   Schoenlein, Patricia V ^a   Delk, Jennifer ^a   Liu, Kebin ^a   Thangaraju, Muthusmy ^a   Dulin, Nickolai O ^b   Ganapathy, Vadivel ^a   Berger, Franklin G ^c   Browning, Darren D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

catenin; Angiogenesis; Apoptosis; Cancer; Cyclic guanosine monophosphate; Protein kinase; Xenograft

Indexed keywords

BETA CATENIN; CD31 ANTIGEN; CYCLIC GMP DEPENDENT PROTEIN KINASE; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; COLON CARCINOGENESIS; COLON CARCINOMA; COLON METASTASIS; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; COLONIC NEOPLASMS; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 41149096647     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23334     Document Type: Article

References (36)

1. Carrithers SL. Diarrhea or colorectal cancer: can bacterial toxins serve as a treatment for colon cancer? Proc Natl Acad Sci USA. 2003;100:3018-3020.
2. Pitari GM, Zingman LV, Hodgson DM, et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc Natl Acad Sci USA. 2003;100:2695-2699.
3. Uzzau S, Fasano A. Cross-talk between enteric pathogens and the intestine. Cell Microbiol. 2000;2:83-89.
4. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci USA. 2001;98:7846-7851.
5. Forte LR Jr. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther. 2004; 104:137-162.
6. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1-24.
7. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev. 1999;18: 15-30.
8. Behrens J. Control of beta-catenin signaling in tumor development. Ann NY Acad Sci. 2000;910:21-33; discussion 33-35.
9. Hanson CA, Miller JR. Non-traditional roles for the adenomatous polyposis coli (APC) tumor suppressor protein. Gene. 2005;361:1-12.
10. Strate LL, Syngal S. Hereditary colorectal cancer syndromes. Cancer Causes Control. 2005;16:201-213.
11. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003; 129:199-221.
12. Pitari GM, Baksh RI, Harris DM, Li P, Kazerounian S, Waldman SA. Interruption of homologous desensitization in cyclic guanosine 3′,5′-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res. 2005;65:11129-11135.
13. Piazza GA, Thompson WJ, Pamukcu R, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res. 2001;61:3961-3968.
14. [No authors listed] Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone. Drugs R D. 2004;5:220-226.
15. Goluboff ET. Exisulind, a selective apoptotic antineoplastic drug. Expert Opin Investig Drugs. 2001;10:1875-1882.
16. Liu L, Li H, Underwood T, et al. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther. 2001; 299:583-592.
17. Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res. 2004;64: 3966-3973.
18. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem. 2005;94:336-350.
19. Kazerounian S, Pitari GM, Shah FJ, et al. Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins. J Pharmacol Exp Ther. 2005;314:1013-1022.
20. Haanen C. Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001;2:677-683.
21. Pitari GM, Li T, Baksh RI, Waldman SA. Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. Mol Cancer Ther. 2006;5:1190-1196.
22. Hou Y, Gupta N, Schoenlein P, et al. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett. 2006;240:60-68.
23. Browning DD, Mc Shane M, Marty C, Ye RD. Functional analysis of type 1alpha cGMP-dependent protein kinase using green fluorescent fusion proteins. J Biol Chem. 2001; 276:13039-13048.
24. Browning DD, McShane MP, Marty C, Ye RD. Nitric oxide activation of p38 mitogen-activated protein kinase in 293T fibroblasts requires cGMP-dependent protein kinase. J Biol Chem. 2000;275:2811-2816.
25. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem. 2006;281:9971-9976.
26. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60: 3338-3342.
27. Soh JW, Mao Y, Kim MG, et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000;6:4136-4141.
28. Soh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem. 2001;276:16406-16410.
29. van Es JH, Barker N, Clevers H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev. 2003;13:28-33.
30. Harris TJ, Peifer M. Decisions, decisions: beta-catenin chooses between adhesion and transcription. Trends Cell Biol. 2005;15:234-237.
31. Easwaran V, Lee SH, Inge L, et al. Beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003;63:3145-3153.
32. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001;61:6050-6054.
33. Hou Y, Wong E, Martin J, Schoenlein PV, Dostmann WR, Browning DD. A role for cyclic-GMP dependent protein kinase in anoikis. Cell Signal. 2006;18:882-888.
34. Rice PL, Peters SL, Beard KS, Ahnen DJ. Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways. Mol Cancer Ther. 2006;5:746-754.
35. Sund M, Zeisberg M, Kalluri R. Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application. Gastroenterology. 2005; 129:2076-2091.
36. Zhao X, Zhuang S, Chen Y, Boss GR, Pilz RB. Cyclic GMP-dependent protein kinase regulates CCAAT enhancer-binding protein β functions through inhibition of glycogen synthase kinase-3. J Biol Chem. 2005;280:32683-32692.